Tango Therapeutics Q4 net loss widens

Reuters03-05
Tango <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 net loss widens

Overview

  • Biotechnology firm reported Q4 net loss of $38.7 mln vs $30.8 mln loss a year ago; no collaboration revenue

  • Company holds $343 mln cash, funding operations into 2028

  • Company advancing vopimetostat trials in pancreatic cancer, enters new collaborations

Outlook

  • Tango plans to start a pivotal study for vopimetostat in pancreatic cancer in 2026

  • Initial data from vopimetostat + RAS$(ON)$ inhibitors study expected in 2026

  • Tango's cash runway extends into 2028, supporting clinical initiatives

Result Drivers

  • VOPIMETOSTAT TRIALS - Strong enrollment in vopimetostat + RAS(ON) inhibitors combination study, showing early safety and efficacy

  • NEW SUPPLY AGREEMENT - Tango entered a supply agreement with Erasca to evaluate vopimetostat with ERAS-0015 in clinical trials

  • ROBUST CASH POSITION - Company holds $343 mln cash, funding operations into 2028

Company press release: ID:nGNXbpqw7v

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

-$0.29

Q4 Net Income

-$38.75 mln

Q4 Basic EPS

-$0.29

Q4 Operating Expenses

$41.86 mln

Q4 Operating Income

-$41.86 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Tango Therapeutics Inc is $14.00, about 13.4% above its March 4 closing price of $12.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment